New York-based biotech UroGen Pharma Ltd. reported positive top-line Phase III clinical results with its lead compound, UGN-101 (mitomycin gel, 0.4%), in patients with low-grade upper tract urothelial cancer on Jan. 8, just under a week after the high-profile appointment of Liz Barrett as its president and CEO, and two days before a company presentation at the J.P. Morgan Healthcare Conference.
Upper tract (renal pelvis, ureter) urothelial carcinomas comprise about 5%-10% of all urothelial carcinomas, which can arise along any part...



![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

